Clinical trials: GI Disorders
IBD (Inflammatory Bowel Disease)
The Clinical Efficacy and Influence Factors of Individualized Treatment of Ustekinumab in Crohn's Disease
The loss of response rate of ustekinumab(UST) is high, and the specific mechanism has not yet been elucidated. Our study aimed to retrospectively analyze the clinical efficacy and influence factors of individualized treatment of…
- Trial name
- NCT06785493
- Testing
- Optimized Treatment (OPT)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Ulcerative Colitis
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
The purpose of this study is to gain insight into the exposure-response relationship of golimumab in moderate-to-severe Ulcerative Colitis (UC).
- Trial name
- GO-LEVEL (NCT03124121)
- Testing
- Golimumab
- Where
- United Kingdom
- Volunteers
- 112 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Gastric Carcinoma
Exploration of Lymph Node Metastasis and Tumor Deposit in the Posterior Gastric Mesentery for Distal Gastric Cancer
This study aims to evaluate lymph node metastasis and tumor deposit in the posterior gastric mesentery following distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer.
- Trial name
- zydgc001 (NCT06736847)
- Testing
- distal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision (CME) in gastric cancer
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jichao Qin
Esophageal Squamous Cell Carcinoma (ESCC)
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
This prospective observational study (PKU-ESCC-Monitor) aims to characterize the dynamic evolution of esophageal squamous cell carcinoma (ESCC) using integrated multi-omics, including tissue genomics, ctDNA, imaging features…
- Trial name
- PKU-ESCC (NCT07152535)
- Volunteers
- 255 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer
Participation and Detection Rate of Screening CT Colonography and Screening Sigmoidoscopy
The objectives of this multicenter, randomized trial is to assess the participation rate achievable through two different screening strategies (Computed Tomographic Colonography-CTC and sigmoidoscopy-FS), to compare detection…
- Trial name
- Proteus (NCT01739608)
- Testing
- Invitation to screening
- Where
- Italy
- Volunteers
- 40,945 people
- Sponsor
- Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Metastatic Colorectal Cancer
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab…
- Trial name
- NCT00145314
- Testing
- FLOX (5-fluorouracil/folinic acid/oxaliplatin), FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab, FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab
- Where
- Norway
- Volunteers
- 571 people
- Sponsor
- The Nordic Colorectal Cancer Biomodulation Group
Diverticulum, Esophageal, Post Gastric Surgery Syndrome
MAgnetic Gastrointestinal Universal Septotome: a Safety and Feasibility Study (MAGUS)
A novel magnetic device, called MAgnetic Gastrointestinal Universal Septotome (MAGUS) was designed to improve the Treatment of diverticulum of the esophagus, Pseudo-diverticulum of the upper GI tract, Candy cane syndrome This…
- Trial name
- MAGUS (NCT04480216)
- Testing
- MAGUS
- Where
- Belgium
- Volunteers
- 16 people
- Sponsor
- Erasme University Hospital
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
GIST - Gastrointestinal Stromal Tumor, GIST
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST.
- Conditions
- GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour
- Trial name
- NCT07406633
- Testing
- KQB198, Imatinib (Gleevec)
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Kumquat Biosciences Inc.
Peptic Ulcer Hemorrhage
Supplementary Angiographic Embolization for Peptic Ulcer Bleeding
Peptic ulcer bleeding is a common disorder. Despite optimal endoscopic and medical treatment, there is a high risk of rebleeding and high mortality.
- Trial name
- NCT01125852
- Testing
- Angiographic embolization, Therapeutic endoscopy
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Odense University Hospital
Adenocarcinoma of the Rectum
Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits
Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration.
- Trial name
- COMET (NCT03303547)
- Testing
- MRI mapping to guide pathological sampling of extranodal tumour deposits
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Imperial College London
GERD
Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity
The study aims to evaluate if a GERD treatment programme, in accordance with current regional recommendations, in a company health care setting, has an impact on health related quality of life (HRQoL), symptoms, and productivity…
- Trial name
- NCT00884247
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer
xDRIVE in Metastatic Colorectal Cancer
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer, Metastatic Rectal Adenocarcinoma, Metastatic Rectal Carcinoma
- Trial name
- NCT06929338
- Testing
- Functional precision medicine
- Sponsor
- First Ascent Biomedical Inc.
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
Colorectal Cancer, Colorectal Carcinoma
Increasing Access to Colorectal Cancer Testing (IACCT) for Blacks
The purpose of this research study is to compare a new educational material to another widely available educational brochure. The goal is to see if the new educational material will change knowledge and behaviors about colorectal…
- Trial name
- IACCT (NCT03078348)
- Testing
- Fecal Immunochemical Test (FIT) Kit, Culturally targeted Photo Novella Booklet, Screen for Life Brochure
- Where
- United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer Colorectal
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.
- Trial name
- CETIDYL (NCT04189055)
- Testing
- Cetuximab, Irinotecan
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
Rheumatoid Arthritis, Diabetic Neuropathy
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital…
- Conditions
- Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
- Trial name
- NCT05573685
- Testing
- DiNaMo Study App
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Click Therapeutics, Inc.
Esophageal Squamous Cell Carcinoma
CIK in Treating Patients With Esophageal Cancer
Chemotherapy is the main treatment method for patients with Esophageal Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from…
- Trial name
- NCT02490735
- Testing
- Cytokine-induced Killer Cells
- Volunteers
- 2,000 people
- Sponsor
- The First People's Hospital of Changzhou
Rectal Cancer
Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer
In this study, patients with middle or low rectal cancer will receive robotic radical resection, and will be randomly assigned to receive inferior mesenteric artery lymph nodes dissection or preservation.
- Trial name
- REAL2 (NCT06956976)
- Testing
- Dissection of Inferior Mesenteric Artery Root Lymph Node, Preservation of Inferior Mesenteric Artery Root Lymph Node
- Where
- China
- Volunteers
- 1,596 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.